J Birkmann
Overview
Explore the profile of J Birkmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoeres T, Wilhelm M, Smetak M, Holzmann E, Schulze-Tanzil G, Birkmann J
Clin Exp Immunol
. 2017 Dec;
192(1):54-67.
PMID: 29235095
Vascular endothelial growth factor (VEGF) is an important regulator of physiological and pathological angiogenesis. Besides malignant and stromal cells, local immune cells shape VEGF signalling in the tumour microenvironment. Aminobisphosphonates...
2.
Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al.
Blood Cancer J
. 2016 Jul;
6(7):e452.
PMID: 27471868
Current guidelines recommend consolidation with autologous stem cell transplantation (autoSCT) after induction chemotherapy for most patients with peripheral T-cell lymphoma (PTCL). This assumption is based on five prospective phase II...
3.
Korfel A, Weller M, Martus P, Roth P, Klasen H, Roeth A, et al.
Ann Oncol
. 2012 Mar;
23(9):2374-2380.
PMID: 22396446
Background: We evaluated the frequency and prognostic impact of meningeal dissemination (MD) in immunocompetent adult patients with primary central nervous system lymphoma treated in a randomized phase III trial. Patients...
4.
Rech J, Manger B, Lang B, Schett G, Wilhelm M, Birkmann J
Rheumatol Int
. 2011 Jul;
32(6):1827-9.
PMID: 21769488
Still's disease and chronic recurrent multifocal osteomyelitis (CRMO) are febrile rheumatic diseases of unknown etiology, which predominantly affect children but can also have their initial manifestation in adults. Both can...
5.
Smetak M, Kimmel B, Birkmann J, Schaefer-Eckart K, Einsele H, Wilhelm M, et al.
Bone Marrow Transplant
. 2007 Nov;
41(7):643-50.
PMID: 18037935
The ability to selectively deplete or enrich cells of specific phenotype by immunomagnetic selection to reduce the risk of GVHD holds significant promise for application in adoptive immunotherapy. Current clinical-scale...
6.
Fischer L, Thiel E, Klasen H, Birkmann J, Jahnke K, Martus P, et al.
Ann Oncol
. 2006 Apr;
17(7):1141-5.
PMID: 16603598
Background: Standard salvage therapy has not been established for recurrent primary central nervous system lymphoma (PCNSL). We report the final results of a prospective study on topotecan chemotherapy in relapsed...
7.
Wandt H, Schaefer-Eckart K, Frank M, Birkmann J, Wilhelm M
Bone Marrow Transplant
. 2006 Jan;
37(4):387-92.
PMID: 16400342
Prophylactic platelet transfusions are considered as standard in most hematology centers, but there is a long-standing controversy as to whether standard prophylactic platelet transfusions are necessary or whether this strategy...
8.
Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F, et al.
Ann Hematol
. 2002 Mar;
81(2):96-102.
PMID: 11907790
We investigated the efficacy and toxicity of the combination of busulfan, cyclophosphamide, and etoposide (Bu/Cy/VP-16) as a preparative regimen prior to autologous hematopoietic stem cell transplantation (ASCT) in patients with...
9.
Hanel M, Kroger N, Kroschinsky F, Birkmann J, Hanel A, Herbst R, et al.
J Cancer Res Clin Oncol
. 2001 Jun;
127(6):387-95.
PMID: 11414199
Purpose: The aim of the study was to evaluate the feasibility and efficacy of the combination of mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in patients with prognostically unfavorable recurrent and...
10.
Goerner M, Wandt H, Schafer-Eckart K, Birkmann J, Denzel T, Gallmeier W
J Hematother Stem Cell Res
. 2000 Jan;
8(4):387-91.
PMID: 10634176
High-dose chemotherapy with autologous stem cell rescue can result in autotransplantation of tumor cells. A possible approach to reduce tumor cell contamination is the positive selection of CD34+ PBPC, but...